Literature DB >> 3740023

A community-based program of colorectal screening in an asymptomatic population: evaluation of screening tests and compliance.

L Bat, A Pines, E Ron, Y Niv, E Arditi, E Shemesh.   

Abstract

The incidence of colorectal cancer in Ashkenazi Jews is two to three times higher than in non-Ashkenazis. For a community colorectal screening program 1339 asymptomatic Ashkenazis over 40 yr old were asked to participate. Of these 1012 (75%) took Hemoccult II kits [fecal occult blood tests (FOBT)], and 614 (46%) personally returned them. Screenees were interviewed regarding family and personal medical history. Fourteen persons (2.3%) had positive tests, in whom colonoscopy revealed two with cancer (Dukes' B,C) and two with a greater than 2 cm polyp. The remaining 600 persons were invited for flexible sigmoidoscopy (FS) but only 287 (48%) appeared. The mean depth of insertion of the instrument was 50.3 cm (range 30-120), but was poorer for women. FS identified lesions in 28 (9.7%) persons: three had Dukes' A carcinomas and 25 had less than 2 cm adenomatous polyps. Significantly more women than men accepted FOBT, but among those completing FOBT, there was no difference by sex for use of FS. Middle-aged persons (50-69 yr) found screening more acceptable than young or older persons. Among screenees who agreed to undergo FS, a significantly larger fraction had a first relative with colon cancer, or a personal history of colon or female genital neoplasia, compared to those not agreeing to FS. There were no differences in screenees with relatives with noncolon cancer. Eighty-eight couples completed FOBT and were invited for FS. The decision whether or not to participate was made for both members in 81 (92%) couples. In conclusion, effective screening programs have to take into consideration compliance patterns of the target population.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3740023

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers.

Authors:  Y Niv; M Lev-El; G Fraser; G Abuksis; A Tamir
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Facilitating factors for colorectal cancer screening.

Authors:  Corey H Brouse; Randi L Wolf; Charles E Basch
Journal:  J Cancer Educ       Date:  2008 Jan-Mar       Impact factor: 2.037

Review 3.  The pros and cons of fecal occult blood testing for colorectal neoplasms.

Authors:  J B Simon
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 4.  Colorectal carcinoma and Haemoccult. A study of its value in mass screening using meta-analysis.

Authors:  J Windeler; J Köbberling
Journal:  Int J Colorectal Dis       Date:  1987-11       Impact factor: 2.571

5.  Reduction of the incidence and mortality of rectal cancer by polypectomy: a prospective cohort study in Haining County.

Authors:  Shu Zheng; Xi-Yong Liu; Ke-Feng Ding; Lin-Bo Wang; Pei-Lin Qiu; Xin-Feng Ding; Yong-Zhou Shen; Gao-Fei Shen; Qi-Rong Sun; Wei-Dong Li; Qi Dong; Su-Zhan Zhang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

6.  Beliefs associated with fecal occult blood test and colonoscopy use at a worksite colon cancer screening program.

Authors:  Usha Menon; Victoria L Champion; Gregory N Larkin; Terrell W Zollinger; Priscilla M Gerde; Sally W Vernon
Journal:  J Occup Environ Med       Date:  2003-08       Impact factor: 2.162

7.  Screening flexible sigmoidoscopy: patient attitudes and compliance.

Authors:  B D McCarthy; M A Moskowitz
Journal:  J Gen Intern Med       Date:  1993-03       Impact factor: 5.128

8.  As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.

Authors:  M Parekh; A M Fendrick; U Ladabaum
Journal:  Aliment Pharmacol Ther       Date:  2008-01-29       Impact factor: 8.171

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.